Cargando…

Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data...

Descripción completa

Detalles Bibliográficos
Autores principales: Solek, Julia, Chrzanowski, Jedrzej, Cieslak, Adrianna, Zielinska, Aleksandra, Piasecka, Dominika, Braun, Marcin, Sadej, Rafal, Romanska, Hanna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138378/
https://www.ncbi.nlm.nih.gov/pubmed/35625798
http://dx.doi.org/10.3390/biomedicines10051061
_version_ 1784714610511708160
author Solek, Julia
Chrzanowski, Jedrzej
Cieslak, Adrianna
Zielinska, Aleksandra
Piasecka, Dominika
Braun, Marcin
Sadej, Rafal
Romanska, Hanna M.
author_facet Solek, Julia
Chrzanowski, Jedrzej
Cieslak, Adrianna
Zielinska, Aleksandra
Piasecka, Dominika
Braun, Marcin
Sadej, Rafal
Romanska, Hanna M.
author_sort Solek, Julia
collection PubMed
description Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence.
format Online
Article
Text
id pubmed-9138378
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91383782022-05-28 Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2 Solek, Julia Chrzanowski, Jedrzej Cieslak, Adrianna Zielinska, Aleksandra Piasecka, Dominika Braun, Marcin Sadej, Rafal Romanska, Hanna M. Biomedicines Review Increasing evidence suggests that the significance of the tumour immune microenvironment (TIME) for disease prognostication in invasive breast carcinoma is subtype-specific but equivalent studies in ductal carcinoma in situ (DCIS) are limited. The purpose of this paper is to review the existing data on immune cell composition in DCIS in relation to the clinicopathological features and molecular subtype of the lesion. We discuss the value of infiltration by various types of immune cells and the PD-1/PD-L1 axis as potential markers of the risk of recurrence. Analysis of the literature available in PubMed and Medline databases overwhelmingly supports an association between densities of infiltrating immune cells, traits of immune exhaustion, the foci of microinvasion, and overexpression of HER2. Moreover, in several studies, the density of immune infiltration was found to be predictive of local recurrence as either in situ or invasive cancer in HER2-positive or ER-negative DCIS. In light of the recently reported first randomized DCIS trial, relating recurrence risk with overexpression of HER2, we also include a closing paragraph compiling the latest mechanistic data on a functional link between HER2 and the density/composition of TIME in relation to its potential value in the prognostication of the risk of recurrence. MDPI 2022-05-03 /pmc/articles/PMC9138378/ /pubmed/35625798 http://dx.doi.org/10.3390/biomedicines10051061 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Solek, Julia
Chrzanowski, Jedrzej
Cieslak, Adrianna
Zielinska, Aleksandra
Piasecka, Dominika
Braun, Marcin
Sadej, Rafal
Romanska, Hanna M.
Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title_full Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title_fullStr Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title_full_unstemmed Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title_short Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2
title_sort subtype-specific tumour immune microenvironment in risk of recurrence of ductal carcinoma in situ: prognostic value of her2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138378/
https://www.ncbi.nlm.nih.gov/pubmed/35625798
http://dx.doi.org/10.3390/biomedicines10051061
work_keys_str_mv AT solekjulia subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT chrzanowskijedrzej subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT cieslakadrianna subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT zielinskaaleksandra subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT piaseckadominika subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT braunmarcin subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT sadejrafal subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2
AT romanskahannam subtypespecifictumourimmunemicroenvironmentinriskofrecurrenceofductalcarcinomainsituprognosticvalueofher2